Gene therapy trial aims to help boys with duchenne walk stronger

NCT ID NCT07160634

Recruiting now Disease control Sponsor: Solid Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests a one-time gene therapy called SGT-003 in 80 boys with Duchenne muscular dystrophy who can still walk. The goal is to see if it helps them move better, like standing up faster and climbing stairs. Participants will receive either the therapy or a placebo first, then switch, and be followed for at least 5 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY

Contacts and locations

Show contact details

Locations

Alberta Children's Hospital
RECRUITING

Calgary, Alberta, T3B 6A8, Canada
Arkansas Children's Hospital
NOT_YET_RECRUITING

Little Rock, Arkansas, 72202, United States
BC Children's Hospital
RECRUITING

Vancouver, British Columbia, Canada
Children's Hospital of the King's Daughters
NOT_YET_RECRUITING

Norfolk, Virginia, 23510, United States
Neurology Rare Disease Center
NOT_YET_RECRUITING

Flower Mound, Texas, 75082, United States

Contact Email: •••••@•••••
The Children's Hospital of Westmead
RECRUITING

Sydney, New South Wales, Australia
The Hospital for Sick Children (SickKids)
RECRUITING

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.